Novadaq Technologies Inc.TSX: NDQ

Novadaq Receives U.S. Patent for Intra-Operative Imaging Procedure Using the SPY System

· Issued by Novadaq Technologies Inc. via CNW
-Patent strengthens IP portfolio-

TORONTO, July 12 /CNW/ - Novadaq Technologies Inc. (TSX: NDQ) today
announced that it has been granted a patent by the United States Patent and
Trademark Office for the SPY(TM) Intra-operative Imaging System (SPY System).
The SPY System enables real-time visual confirmation of revascularization
during heart bypass surgery thereby allowing bypass graft technical errors to
be detected and corrected while the patient is still in the operating room.
"The claims of this patent provide protection for our proprietary SPY
System technology and our intra-operative imaging procedure," said Arun
Menawat, President and CEO of Novadaq Technologies. "This U.S. patent supports
our global strategy to build a strong IP portfolio to protect our innovative
vascular imaging technology products and emerging pipeline."
The patent, U.S. 6,915,154 B1, is titled "Method and Apparatus For
Performing Intra-Operative Angiography" and describes the SPY intra-operative
fluorescent imaging system that enables cardiac surgeons to confirm the
location of coronary arteries during coronary artery bypass graft (CABG)
procedures and visually assess and validate the functionality of bypass
grafts.

About the SPY Intra-operative Imaging System
Novadaq's SPY Intra-operative Imaging System has received 510(k)
clearance from the U.S. Food and Drug Administration (FDA) for use during CABG
surgery. The SPY System is the first intra-operative fluorescent imaging
system that enables cardiac surgeons to confirm the location of the coronary
arteries and assess bypass graft functionality during coronary artery bypass
procedures. The SPY System enables the surgeon to view, record, replay, print
and archive high quality real-time images of the coronary arteries and bypass
grafts.

About Novadaq Technologies
Novadaq(TM) Technologies (TSX: NDQ) develops and commercializes medical
devices based on its proprietary imaging platform for the diagnosis and
treatment of human vascular and ophthalmic diseases and conditions. Novadaq's
SPY System enables surgeons to visually assess coronary vasculature and bypass
graft functionality during the course of CABG surgery. Novadaq's ophthalmic
product, OPTTX(TM) System, is aimed at the diagnosis, evaluation and treatment
of Wet Age Related Macular Degeneration (AMD) by using the same core imaging
technology that is used in the SPY. The OPTTX System is currently being
evaluated in clinical trials.
For more information, please visit the company's website at
www.novadaq.com.


Certain statements included in this press release may be considered
forward-looking. Such statements involve known and unknown risks,
uncertainties and other factors that may cause actual results, performance or
achievements to be materially different from those implied by such statements,
and therefore these statements should not be read as guarantees of future
performance or results. All forward-looking statements are based on Novadaq's
current beliefs as well as assumptions made by and information currently
available to Novadaq and relate to, among other things, anticipated financial
performance, business prospects, strategies, regulatory developments, market
acceptance and future commitments. Readers are cautioned not to place undue
reliance on these forward-looking statements, which speak only as of the date
of this press release. Due to risks and uncertainties, including the risks and
uncertainties identified by Novadaq in its public securities filings; actual
events may differ materially from current expectations. Novadaq disclaims any
intention or obligation to update or revise any forward-looking statements,
whether as a result of new information, future events or otherwise.

%SEDAR: 00022069E

Novadaq Technologies Inc. on 6ix

Earlier from Novadaq Technologies

Later from Novadaq Technologies

All Novadaq Technologies news releases